ZA200501871B - Use of saccharomyces cerevisiae erg4 mutants for the expression of glucose transporters from mammals - Google Patents
Use of saccharomyces cerevisiae erg4 mutants for the expression of glucose transporters from mammals Download PDFInfo
- Publication number
- ZA200501871B ZA200501871B ZA2005/01871A ZA200501871A ZA200501871B ZA 200501871 B ZA200501871 B ZA 200501871B ZA 2005/01871 A ZA2005/01871 A ZA 2005/01871A ZA 200501871 A ZA200501871 A ZA 200501871A ZA 200501871 B ZA200501871 B ZA 200501871B
- Authority
- ZA
- South Africa
- Prior art keywords
- protein
- yeast cell
- yeast
- polynucleotide
- glucose
- Prior art date
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims description 86
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 title claims description 84
- 108091052347 Glucose transporter family Proteins 0.000 title claims description 31
- 102000042092 Glucose transporter family Human genes 0.000 title claims description 26
- 101100389668 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) erg-4 gene Proteins 0.000 title claims description 19
- 241000124008 Mammalia Species 0.000 title description 5
- 210000005253 yeast cell Anatomy 0.000 claims description 85
- 108090000623 proteins and genes Proteins 0.000 claims description 84
- 102000004169 proteins and genes Human genes 0.000 claims description 74
- 108091033319 polynucleotide Proteins 0.000 claims description 51
- 102000040430 polynucleotide Human genes 0.000 claims description 51
- 239000002157 polynucleotide Substances 0.000 claims description 51
- 150000001875 compounds Chemical class 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 25
- 239000008103 glucose Substances 0.000 claims description 25
- 108091006300 SLC2A4 Proteins 0.000 claims description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
- 230000004190 glucose uptake Effects 0.000 claims description 23
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 claims description 9
- 108091006296 SLC2A1 Proteins 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 6
- 230000001131 transforming effect Effects 0.000 claims description 6
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 101000906283 Homo sapiens Solute carrier family 2, facilitated glucose transporter member 1 Proteins 0.000 claims description 4
- 101000996127 Homo sapiens Solute carrier family 2, facilitated glucose transporter member 4 Proteins 0.000 claims description 4
- 102000052262 human SLC2A4 Human genes 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 101150040602 ERG4 gene Proteins 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 102100031673 Corneodesmosin Human genes 0.000 claims 1
- 101710139375 Corneodesmosin Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000005714 functional activity Effects 0.000 claims 1
- 102000052191 human SLC2A1 Human genes 0.000 claims 1
- 239000013598 vector Substances 0.000 description 32
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 108010078791 Carrier Proteins Proteins 0.000 description 14
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 150000002402 hexoses Chemical class 0.000 description 5
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 102000005455 Monosaccharide Transport Proteins Human genes 0.000 description 3
- 108010006769 Monosaccharide Transport Proteins Proteins 0.000 description 3
- 101100507956 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HXT7 gene Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-UKLRSMCWSA-N dextrose-2-13c Chemical compound OC[C@H]1OC(O)[13C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-UKLRSMCWSA-N 0.000 description 3
- 230000006377 glucose transport Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 101150030468 MPH3 gene Proteins 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 101100024083 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MPH2 gene Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000005567 liquid scintillation counting Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 206010000188 Abnormal weight gain Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 101000899738 Drosophila melanogaster Glucose transporter type 3 Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 201000006328 Fanconi syndrome Diseases 0.000 description 1
- 208000037251 Fanconi-Bickel syndrome Diseases 0.000 description 1
- 101150037782 GAL2 gene Proteins 0.000 description 1
- 101710193897 Galactose transporter Proteins 0.000 description 1
- 101710103223 Galactose-proton symporter Proteins 0.000 description 1
- 102100021735 Galectin-2 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100030624 Proton myo-inositol cotransporter Human genes 0.000 description 1
- 108091006310 SLC2A12 Proteins 0.000 description 1
- 108091006309 SLC2A13 Proteins 0.000 description 1
- 108091006299 SLC2A2 Proteins 0.000 description 1
- 101100507949 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HXT2 gene Proteins 0.000 description 1
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 1
- 102100039671 Solute carrier family 2, facilitated glucose transporter member 12 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 208000019061 glycogen storage disease due to GLUT2 deficiency Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102220034167 rs137853903 Human genes 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/18—Baker's yeast; Brewer's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
I'S + WO 2004/026907 PCT/EP2003/009812 @.-- of Saccharomyces cerevisiae erg4 mutants for the expression of glucose transporters from mammals.
The invention relates to yeast strains in which the human Glut 4 and Glut 1 transporters can be functionally expressed.
Most heterotropic cells transport glucose via special transporter proteins into the cell interior. The various organisms have developed different mechanisms mediating the transporting of glucose, such as, in particular, proton symport systems, Na* glucose transporters, binding protein-dependent systems, phosphotransferase systems, and systems for facilitated diffusion. In the eukaryotes, a family of glucose transporters which are encoded in mammals by the GLUT genes (GLUT = glucose transporter) and Saccharomyces cerevisiae by the HXT genes (HXT = hexose transporter) mediates glucose uptake via facilitated diffusion. Said transporters belong to a larger family of sugar transporters. They are characterized by the presence of 12 transmembrane helices and by a plurality of conserved amino acid radicals.
Glucose transport plays an important part in disorders associated with a defective glucose homeostasis, such as, for example, diabetes mellitus or Fanconi-Bickel syndrome. The glucose transport in mammals has therefore been the subject of numerous studies. To date, thirteen glucose transporter-like proteins have been identified (GLUT1 to GLUT12, HMIT — H-myo-inositot transporter)) . Said transporters play key parts which include the uptake of glucose into various tissues, its storage in the liver, its insulin-dependent uptake into muscle cells and adipocytes and glucose measurement by the B cells of the pancreas.
GLUT1 mediates the transport of glucose into erythrocytes and through the blood- brain barrier, but is also expressed in many other tissues, while GLUT4 is limited to insulin-dependent tissues, primarily to muscle and fatty tissue. In said insulin- dependent tissues, controlling the targeting of GLUT4 transporters through intracellular compartments or plasma membrane compartments represents an important mechanism for regulating glucose uptake. In the presence of insulin, intracellular GLUT 4 is redistributed through the plasma membrane in order to facilitate glucose uptake. GLUT1 is likewise expressed in said insulin-dependent
Pp , 2 : tissues, and its distribution in the cell is likewise influenced by insulin, albeit not as
N— In addition, the relative efficacy with which GLUT1 or GLUT4 catalyze sugar transport is determined not only by the extent of the targeting of each transporter to the cell surface but also by their kinetic properties.
The fact that different glucose transporter isoforms are coexpressed and the rapid glucose metabolism have rendered studies on the role and the exact properties of each glucose transporter isoform in these insulin-dependent tissues complicated. In order to solve these problems, heterologous expression systems such as Xenopus oocytes, tissue culture celis, insect cells and yeast cells have been used. However, it turned out that a number of difficulties appeared in connection with these systems: too weak an activity of the heterologously expressed transporters, intrinsic glucose transporters in said systems, intracellular retention of a considerable proportion of the transporters or even production of inactive transporters.
Naturally occurring GLUT4 protein of mammals, in particular that of humans, can be expressed in a functional manner in strains of Saccharomyces cerevisiae under particular conditions.
Yeast cells are unicell eukaryotic organisms. They are therefore, for some proteins, more suitable for expression than bacterial systems, in particular with regard to carrying out screen assays for identifying pharmaceutically active substances.
The present invention relates to a purified and isolated polynucleotide comprising a
DNA sequence which codes for the GLUT4V85M protein.
Said protein contains at position 85 of the amino acid chain of the human GLUT4 protein an amino acid exchange from valine to methionine. This altered GLUT4V85M protein provides further alternatives for expressing a functional GLUT4 protein. A
GLUT4 protein should be regarded as functional in connection with Saccharomyces cerevisiae if glucose uptake can be observed in a Saccharomyces cerevisiae strain whose glucose transporters in their entirety are inactive (=hxt(-)) after expression of said GLUT4 protein. Glucose uptake may be determined either by transport measurements by means of radioactively labeled glucose or by growth on medium with glucose as sole carbon source.
In a preferred embodiment, the purified and isolated polynucleotide comprising a @ona sequence which calls for a protein GLUT4V85M may include or comprise a sequence of the following groups: a) a nucleotide sequence according to Seq ID No. 1, b) a nucleotide sequence which hybridizes to a sequence of Seq ID No. 1 under stringent conditions and which codes for a protein GLUT4V85M.
The purified and isolated polynucleotide preferably encodes a GLUT4V85M protein which has an amino acid sequence of Seq ID No. 2.
The purified and isolated polynucleotide comprising a DNA sequence which codes as discussed previously for a protein GLUT4V85M, may be operationally linked to a promotor. Suitable promotors are in particular prokaryotic or eukaryotic promoters such as, for example, the Lac-, trp-, ADH- or HXT7 promotor. The part of the polynucleotides, which codes for the protein GLUT4V85M is operationally linked to a promotor precisely if a bacterial or eukaryotic organism produces, by means of said promotor with the aid of a vector, an mRNA which can be translated into the protein
GLUT4V85M. An example of such a vector is the vector p4H7GLUT4V85M (Seq ID
No. 3). The protein GLUT4V85M may be expressed in yeast cells by means of said vector.
The above-described polynucleotide comprising a DNA sequence which codes for a protein GLUT4V85M is, in a preferred embodiment, suitable for replicating said polynucleotide in a yeast cell or for expressing the part of the polynucleotide, which encodes the protein GLUT4V85M, in a yeast cell to give the protein GLUT 4 V85M.
A yeast cell from Saccharomyces cerevisiae is particularly suitable. For replication and expression in a yeast cell, the polynucleotide comprising a DNA sequence which calls for a protein GLUT4V85M is present in the form of a yeast vector. The polynucleotide region coding for the GLUT4V85M protein may be operationally linked to a yeast cell-specific promotor such as, for example, the ADH promotor (alcohol dehydrogenase promotor) or the HXT7 promotor (hexose-transporter promotor). The yeast sectors are a group of vectors which was developed for cloning of DNA in yeasts.
The invention furthermore relates to a yeast cell from Saccharomyces cerevisiae in which all glucose transporters are no longer functional (=hxt (-)) and which contains
PE 4 ’ no functional Erg4 protein. Such a yeast cell is preferably a yeast cell deposited as @saccharomyces cerevisiae DSM 15187 with the DSMZ (Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 16, 38124 Brunswick,
Germany).
The invention also relates to a yeast cell in which all glucose transporters are no longer functional and which contains no functional Fgy1 and no functional Erg4 protein. The lack of an Erg4 protein or of an Fgy1 protein may be attributed in particular to an interruption of the corresponding coding genome sections or to a partial or complete removal of said coding genome sections.
Preference is given to using as yeast cell which contains no functional glucose transporters, no functional Fgy1 protein and no functional Erg4 protein, a yeast cell as deposited with the DSMZ as Saccharomyces cerevisiae DSM 15184.
A yeast cell as described above is preferably used for expressing a mammalian
GLUT1 protein or a mammalian GLUT4 protein, in particular a protein from rats, mice, rabbits, pigs, cattle or primates. A preferred embodiment uses the yeast cell for expressing a human GLUT4 or GLUT1 protein.
A Saccharomyces cerevisiae yeast cell whose glucose transporters in their entirety and also the Erg4 protein are no longer functional may contain a polynucleotide of the present invention, which comprises a DNA sequence coding for a protein
GLUT4V85M. Said yeast cell can also express the GLUT4V85M protein and thus contain said protein.
A yeast strain of this kind, containing a polynucleotide which comprises a DNA sequence coding for the GLUT4V85M protein, is preferably the Saccharomyces cerevisiae DSM 15185 yeast strain which has been deposited with the DMSZ.
A yeast cell whose glucose transporters in their entirety and also the Erg4 protein are no longer functional and which contains a polynucleotide comprising a DNA sequence which calls for a protein GLUT4V85M may be prepared, for example, by a) providing a yeast cell whose glucose transporters in their entirety and also the
Erg4 protein are no longer functional, b) providing an isolated and purified polynucleotide which comprises a DNA sequence coding for the GLUT4V85M protein and which can be replicated in the yeast cell, c) transforming the yeast cell from a) with the polynucleotide from b),
: d) selecting a transformed yeast cell, ® e) where appropriate expressing the GLUT4V85M protein.
An isolated and purified polynucleotide which comprises a DNA sequence coding for the GLUT4V85M protein is preferably a vector which can be replicated in a yeast cell and in which said DNA sequence was cloned. An example of such a vector is p4H7GLUT4V85M (Seq ID No. 3).
The invention also relates to a yeast cell whose glucose transporters in their entirety and whose proteins for Fgy1 and Erg4 are no longer functional and which contains a polynucleotide which comprises a DNA sequence coding for the GLUT4V85M protein. Said yeast cell can also express the GLUT4V85M protein and thus contain said protein. A yeast strain of this kind is preferably the Saccharomyces cerevisiae
DSM 15186 deposited with the DSMZ.
A yeast cell whose glucose transporters in their entirety and also the proteins Fgy1 and Erg4 are no longer functional and which contains a polynucleotide comprising a
DNA sequence which codes for the GLUT4V85M protein may be prepared, for example, by a) providing a yeast cell whose glucose transporters in their entirety and also the proteins Fgy1 and Erg4 are no longer functional, b) providing an isolated and purified polynucleotide which comprises a DNA sequence coding for the GLUT4V85M protein and which can be replicated in the yeast cell, c) transforming the yeast cell from a) with the polynucleotide from b), d) selecting a transformed yeast cell, e) where appropriate expressing the GLUT4V85M protein.
The abovementioned isolated and purified polynucleotide which comprises a DNA sequence coding for the GLUT4V85M protein is preferably a vector which can be replicated in a yeast cell and in which said DNA sequence was cloned. An example of such a vector is pAH7GLUT4V85M (Seq ID No. 3).
Lo. 6 ’ The invention also relates to a yeast cell whose glucose transporters in their entirety (J no longer functional and which contains a polynucleotide comprising a DNA sequence which calls for the GLUT4V85M protein.
Said yeast cell can also express the GLUT4V85M protein and thus contain said protein. A preferred yeast strain of this kind is the Saccharomyces cerevisiae 15188 yeast strain deposited with the DSMZ.
A yeast cell whose glucose transporters in their entirety are no longer functional and which contains a polynucleotide comprising a DNA sequence which codes for the
GLUT4 V85M protein may be prepared, for example, by a) providing a yeast cell whose glucose transporters in their entirety are no longer functional, b) providing an isolated and purified polynucleotide which comprises a DNA sequence coding for the GLUT4V85M protein and which can be replicated in the yeast cell, c) transforming the yeast cell from a) with the polynucleotide from b), d) selecting a transformed yeast cell, e) where appropriate expressing the GLUT4V85M protein.
An isolated and purified polynucleotide which comprises a DNA sequence coding for the GLUT4V85M protein is preferably a vector which can be replicated in a yeast cell and in which said DNA sequence was cloned. An example of such a vector is p4H7GLUT4V85M (Seq ID No. 3). .
The invention also relates to a protein having the amino acid sequence according to
Seq ID No. 2. Said protein is a human GLUT4 protein in which a valine has been replaced by a methionine in position 85 of the amino acid chain.
The invention also relates to a method for identifying a compound which stimulates the activity of a GLUT4 protein, which method comprises the steps a) providing a yeast cell whose glucose transporters in their entirety and also
Erg4 protein are no longer functional and which contains a polynucleotide comprising a DNA sequence which codes for a protein GLUT4V85M, b) providing a chemical compound, c) contacting the yeast of a) with the chemical compound of b),
Lo 7 d) determining glucose uptake by the yeast of c), o e) relating the detected value of the glucose uptake of d) to the detected value of glucose uptake in a yeast cell as claimed in a) which has been contacted with a chemical compound as claimed in b), with a compound which causes an increase in the amount of glucose taken up in the yeast as claimed in d) stimulating the activity of said GLUT4 protein. Compounds which stimulate the activity of the GLUT4V85M protein can be assumed to stimulate also the
GLUT4 activity.
The invention also relates to a pharmaceutical which contains a compound which has been identified by the method described above and furthermore to additives and excipients for formulating a pharmaceutical. Furthermore, the invention relates to the use of a compound which has been identified by the method described above for producing a pharmaceutical for the treatment of type | and/or ll diabetes.
The invention also relates to a pharmaceutical comprising a compound which has been identified by the method described above and to additives and excipients for formulating a pharmaceutical. Furthermore, the invention relates to the use ofa compound identified by the method described above for producing a pharmaceutical for the treatment of diabetes.
The invention furthermore relates to the use of a compound identified by a method described above for producing a pharmaceutical for the treatment of diabetes. p
The present invention also comprises a method for identifying a compound which inhibits the protein encoded by the Erg4 gene, which method comprises the steps: a) providing a yeast cell whose glucose transporters in their entirety and no longer functional and which contains a polynucleotide comprising a DNA sequence which codes for the GLUT4V85M protein and can be replicated in a yeast cell, b) providing a chemical compound c) contacting the yeast of a) with the chemical compound of b), d) determining glucose uptake by the yeast of c), e) relating the detected value of the glucose uptake of d) to the detected value of glucose uptake in a yeast cell as claimed in a) which is not contacted with a
PE 8 ’ chemical compound as claimed in b), with a compound which causes an ® increase in the amount of glucose taken up in the yeast as claimed in d) stimulating the activity of a protein Erg4.
The invention furthermore relates to a method for identifying a compound inhibiting the corresponding protein of the Fgy1 gene, which comprises the steps: a) providing a yeast cell whose glucose transporters in their entirety and whose
Erg4 protein are no longer functional and which contains a GLUT4 protein, b) providing a chemical compound c) contacting the yeast of a) with the chemical compound of b), d) determining glucose uptake by the yeast of c), e) relating the detected value of the glucose uptake of d) to the detected value of glucose uptake in a yeast cell as claimed in a) which is not contacted with a chemical compound as claimed in b), with a compound which causes an increase in the amount of glucose taken up in the yeast as claimed in d) stimulating the activity of a protein Fgy1.
The invention also relates to a pharmaceutical comprising a compound which has been identified by the method described above and to additives and excipients for formulating a pharmaceuttical.
The invention may be illustrated in more detail below with respect to technical details. ,
Hybridization means the assembling of two nucleic acid single strands having complementary base sequences to double strands. Hybridization may take place between two DNA strands, one DNA and one RNA strand and between two RNA strands. In principle, it is possible to prepare hybrid molecules by heating the nucleic acids involved which may initially be in double-stranded form, by boiling, for example, in a waterbath for 10 minutes, until they disintegrate into single-stranded molecules without secondary structure. Subsequently, they can be cooled slowly.
During the cooling phase, complementary chains pair to give double-stranded hybrid molecules. Under laboratory conditions, hybridizations are usually carried out with the aid of hybridization filters to which single-stranded or denaturable polynucleotide
Pp 9 } molecules are applied by blotting or electrophoresis. It is possible to visualize the @ bridization using appropriate complementary polynucleotide molecules by providing said polynucleotide molecules to be hybridized with a radioactive fluorescent label. Stringency describes the degree of matching or alignment of particular conditions. High stringency has higher demands on matching than low stringency. Depending on the application and objective, particular conditions with different stringency are set for the hybridization of nucleic acids. At high stringency, the reaction conditions for the hybridization are set in such a way that only complementary molecules which match very well can hybridize with one another.
Low stringency enables molecules also to partially hybridize with relatively large sections of unpaired or mispaired bases.
The hybridization conditions are to be understood as being stringent, in particular, if the hybridization is carried out in an aqueous solution containing 2 x SSC at 68°C for atleast 2 hours, followed by washing first in 2x SSC/0.1 % SDS at room temperature for 5 minutes, then in 1 x SSC/0.1 % SDS at 68 °C for 1 hour and then in 0.2%
SSC/0.1% SDS at 68°C for another hour.
A 2x SSC, 1x SSC or 0.2 x SSC solution is prepared by diluting a 20 x SSC solution appropriately. A 20 x SSC solution contains 3 mol/l NaCl and 0.3 mol/l Na citrate. The pH is 7.0. The skilled worker is familiar with the methods for hybridizations of polynucleotides under stringent conditions. Appropriate instructions can be found in specialist books such as, in particular, Current Protocols in ,
Molecular Biology (Wiley Interscience; editors: Frederich M. Ausubel, Roger Brant,
Robert E. Kingston, David J. Moore, J. G. Seidmann, Kevin Struhl; ISBN: 0-471- 50338-X).
The yeast vectors can be divided into different subgroups. Ylp vectors (yeast integrating plasmids) essentially correspond to the vectors used in bacteria for clonings, but contain a selectable yeast gene (e.g. URA3, LEU2).
Only when the foreign DNA integrates into a yeast chromosome after introduction of said vector, are these sequences replicated together with the chromosome and, with the formation of a clone, stably transferred to all daughter cells.
: Based on this method, plasmids have been derived which can replicate @-.onomousty owing to eukaryotic ORIs (origins of replication). Such yeast vectors are referred to as YRp vectors (yeast replicating plasmids) or ARS vectors (autonomously replicating sequence). Furthermore, there are YEp vectors (yeast episomal plasmids) which are derived from the yeast 2um plasmid and which contain a selective marker gene. The class of the YAC vectors (yeast artificial chromosome) behave like independent chromosomes.
A yeast vector containing a gene to be expressed is introduced into the yeast by means of transformation in order for said gene to be able to be expressed. Examples of methods suitable for this purpose are electroporation or incubation of competent cells with vector DNA. Suitable yeast expression promoters are known to the skilled worker, examples being the SOD1 promotor (superoxide dismutase), ADH promotor (alcohol dehydrogenase), the promotor of the gene for acidic phosphatase, HXT2 promotor (glucose transporter 2), HXT7 promotor (glucose transporter 7), GAL2 promotor (galactose transporter) and others. The construct comprising a yeast expression promotor and a gene to be expressed (e.g. GLUT4V85M) is, for the purpose of expression, part of a yeast vector. To carry out expression, said yeast vector may be a self-replicating particle which is independent of the yeast genome or may be stably integrated into the yeast genome. A suitable yeast vector is in principle any polynucleotide sequence which can be propagated in a yeast. Yeast vectors which may be used are in particular yeast plasmids or yeast artificial chromosomes. Yeast vectors usually contain an origin of replication (2p, ars) or, starting the replication process and a selection marker which usually comprises an auxotrophy marker or an antibiotic resistance gene. Examples of yeast vectors known to the skilled worker are pBM272, pCS19, pEMBCYe23, pFL26, pG6,
PNN414, pTV3, p426MET25, p4H7 and others.
In accordance with the present invention, selection of a cell means the specific concentration thereof, owing to a selection marker such as, for example, resistance to an antibiotic or the ability to grow on a particular minimal medium, and furthermore the isolation and subsequent cultivation thereof on an agar plate or in submerged culture.
So 11 @cuiivation, transformation and selection of a transformed yeast cell and also expression of a protein in a yeast cell are among the methods commonly used by the skilled worker. Instructions regarding said methods can be found in standard text books, for example in Walker Graeme M.: Yeast Physiology and Biotechnology,
Wiley and Sons, ISBN: 0-471-9446-8 or in Protein Synthesis and Targeting in Yeast,
Ed. Alistair J. P. Brown, Mick F. Fruite and John E. G. Mc Cartly; Springer Berlin;
ISBN: 3-540-56521-3 or in “Methods in Yeast Genetics, 1997: A Cold Spring Harbor
Laboratory Course Manual; Adams Alison (Edt.); Cold Spring Harbor Laboratory;
ISBN: 0-87969-508-0".
The yeast Saccharomyces cerevisiae has 17 known hexose transporters and additionally three known maltose transporters, which are capable of transporting hexoses into said yeast, provided that their expression is sufficiently high. In one known strain all transporters suitable for hexose uptake were removed by deletion.
Said strain contains merely just the two genes MPH2 and MPH3 which are homologous to maltose transport proteins. The two genes MPH2 and MPH3 are repressed in the presence of glucose in the medium. Wieczorke et al., FEBS Lett. 464, 123 — 128 (1999) describe the preparation and characterization of this yeast strain. Said strain is not able to propagate on a substrate containing glucose as sole carbon source. It is possible to select from said strain mutants which functionally express GLUT1, starting from a corresponding vector (hxt fgy1-1 strain).
If the yeast strain hxt fgy1-1 is transformed with a plasmid vector which carries a
GLUT4 gene under control of a yeast promotor, still only very little glucose is transported. Functional GLUT4 expression requires further adjustments to this yeast strain in order to make possible a significant glucose transport by means of GLUT4.
Such yeast strains whose cells take up glucose by means of a single glucose transporter GLUT4 can be isolated on substrates having glucose as sole carbon source. For this purpose, a yeast hxt fgy1-1 strain carrying a GLUT4 gene under the functional control of a yeast promotor is transformed. These yeast cells transformed in this way are applied to a nutrient medium containing glucose as sole carbon source and are incubated thereon. After a few days of incubation at, for example 30 °C, the growth of individual colonies is observed. One of these colonies is isolated.
The removal of the yeast plasmid from said colony prevents propagation on the
PE 12 nutrient medium containing glucose as sole carbon source. If this strain which no [J contains a vector plasmid is again transformed with a yeast vector carrying a
GLUT4 gene under the functional control of a yeast promotor, said strain is then again able to propagate on a medium containing glucose as sole carbon source.
The abovementioned yeast strains are the subject matter of International Application
PCT/EP02/01373, filed on February 9, 2002, which claims the priority of DE 10106718.6 of February 14, 2002.
Yeast strains whose indigenous transporters for hexoses (glucose transporters) in their entirety are no longer functional have already been deposited at an earlier date in connection with International Application PCT/EP02/01373 with the Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under the number
DSM 14035, DSM 14036 or DSM 14037.
The polynucleotide and amino acid sequences of GLUT4 are accessible, for example, via the following entries in gene banks: M20747 (cDNA; human), EMBL:
D28561 (cDNA; rat), EMBL: M23382 (cDNA; mouse), Swissprot: P14672 (protein; human), Swissprot: P19357 (protein; rat) and Swissprot: P14142 (protein; mouse).
Polynucleotide sequences and amino acid sequences of GLUT1 are disclosed under the following code numbers of the databases indicated: EMBL: M20653 (cDNA; human), EMBL: M13979 (cDNA; rat), EMBL: M23384 (cDNA; mouse), Swissprot:
P11166 (protein; human), Swissprot: P11167 (protein: rat) and Swissprot: P17809 (protein; mouse).
Pharmaceuticals are dosage forms of pharmacologically active substances for the therapy of diseases or bodily malfunctions in humans and animals. Examples of dosage forms for oral therapy are powders, granules, tablets, pills, lozenges, sugar- coated tablets, capsules, liquid extracts, tinctures and syrups. Examples which are used for external application are aerosols, sprays, gels, ointments or powders.
Injectable or infusible solutions allow parenteral administration, using vials, bottles or prefilled syringes. These and other pharmaceuticals are known to the skilled worker in the field of pharmaceutical technology.
® for formulating a pharmaceutical made possible the preparation of the active substance with the purpose of optimizing the application, distribution and development of action of the active ingredient for the particular application.
Examples of such excipients are fillers, binders, disintegrants or glidants, such as lactose, sucrose, mannitol, sorbitol, cellulose, starch, dicalcium phosphate, polyglycols, alginates, polyvinylpyrrolidone, carboxymethyicellulose, talc or silicon dioxide.
Diabetes manifests itself by the excretion of glucose together with the urine with an abnormal increase in the blood glucose level (hyperglycaemia), owing to a chronic metabolic condition due to insulin deficiency or reduced insulin action. The lack of, or reduced, insulin action leads to insufficient absorption and conversion by the cells of the glucose taken up into the blood. In fatty tissue, insulin-antagonistic hormones have the effect of increasing lypolysis accompanied by an increase in the free fatty acid levels in the blood.
Adiposity (obesity) is the abnormal weight gain owing to an energy imbalance due to excessive intake of calories, which constitutes a health risk.
The amount of a hexose which is taken up by a provided yeast strain as described just above can be determined by means of uptake studies using radioactively labeled glucose. For this purpose, a particular concentration of the yeast cells is suspehded in, for example, 100 pl of a buffer, for example at a concentration of 60 mg (wet weight) per ml, and admixed with a defined amount of 14C- or 3H-labeled glucose as sole carbon source. The cells are incubated, and defined amounts thereof are removed at specific times. The amount of glucose taken up is determined with the aid of LSC (Liquid Scintillation Counting). The amount of a hexose which is taken up by a yeast strain provided and as just described above may, however, also be determined by means of a growth assay on media containing glucose as sole carbon source. For this purpose, the rate of growth of the strain is determined, after addition of the compound, for example by measuring the optical density of the culture at
Claims (36)
1. A purified and isolated polynucleotide, which comprises a DNA sequence coding for a protein GLUT4V85M.
2. The polynucleotide as claimed in claim 1, which comprises a sequence from any of the following groups: a) a nucleotide sequence according to Seq ID No. 1 b) a nucleotide sequence which hybridizes to a sequence of Seq ID No. 1 under stringent conditions and which codes for a protein GLUT4V85M.
3. The polynucleotide as claimed in claim 1 or 2, wherein the protein GLUT4V85M has an amino acid sequence according to Seq ID No. 2.
4. The polynucleotide as claimed in claims 1 to 3, in which the coding region for the protein GLUT4V85M is operationally linked to a promotor.
5. The polynucleotide as claimed in claim 1 to 4, which can be replicated in a yeast cell.
6. The polynucleotide as claimed in claim 5, which can be used to express a protein in a yeast cell.
7. Avyeast cell from Saccharomyces cerevisiae, wherein all glucose transporters are no longer functional and which contains no functional Erg4 protein.
8. A yeast cell from Saccharomyces cerevisiae, wherein all glucose transporters are no longer functional and which contains no functional Fgy1 protein and no functional Erg4 protein.
9. The yeast cell as claimed in claim 7 or 8, wherein the ERG4 gene is completely or partially deleted.
: 10. The yeast cells as claimed in claim 7, as deposited as Saccharomyces @ cerevisiae DsM 15187.
11. The yeast cells as claimed in claim 8 or 9, as deposited as Saccharomyces cerevisiae DSM 15184.
12. The use of a yeast cell as claimed in claims 15 to 18 for expressing a mammalian GLUT1 protein or GLUT4 protein.
13. The use as claimed in claim 12, for expressing a human GLUT4 protein or a human GLUT1 protein.
14. The yeast cell as claimed in claim 7, comprising a polynucleotide as claimed in claims 1 to 6.
15. The yeast cell as claimed in claim 14, comprising a protein GLUT4V85M.
16. The yeast cell as claimed in claim 14 and/or 15, as deposited as Saccharomyces cerevisiae DSM 15185.
17. A process of preparing a yeast cell as claimed in claims 14 to 16, which comprises the steps: a) providing a yeast cell as claimed in claim 7, , b) providing a polynucleotide as claimed in claim 5 or 6, c) transforming the yeast cell as claimed in a) with the polynucleotide as claimed in b), d) selecting a transformed yeast cell, e) where appropriate, expressing a protein GLUT4V85M.
18. The yeast cell as claimed in claim 8 or 9, comprising a polynucleotide as claimed in claims 1 to 6.
19. The yeast cells claimed in claim 18, comprising a protein GLUT4V85M.
N 33
20. The yeast cell as claimed in claim 18 and/or 19, deposited as Saccharomyces @-rcvisiae DSM 15186.
21. A process of preparing a yeast cell as claimed in claims 18 to 20, which comprises the steps: a) providing a yeast cell as claimed in claim 8 or 9, b) providing a polynucleotide as claimed in claim 5 or 6, c) transforming the yeast cell as claimed in a) with the polynucleotide as claimed in b), d) selecting a transformed yeast cell, e) where appropriate, expressing a protein GLUT4V85M.
22. A yeast cell whose glucose transporters in their entirety are no longer functional, comprising a polynucleotide as claimed in claims 1 to 6.
23. The yeast cell as claimed in claim 22, comprising a protein GLUT4V85M.
24. The yeast cell as claimed in claim(s) 22 and/or 23, deposited as Saccharomyces cerevisiae DSM 15188.
25. A process of preparing a yeast cell as claimed in claims 22 to 24, which comprises the steps: a) producing a yeast cell whose glucose transporters in their entirety are no. longer functional, b) providing a polynucleotide as claimed in claim 5 or 6 c) transforming the yeast cell as claimed in a) with the polynucleotide as claimed in b) d) selecting a transformed yeast cell, e) where appropriate, expressing a protein GLUT4V84M.
26. A protein having the functional activity of a glucose transporter, which is encoded by a polynucleotide sequence as claimed in any of claims 1 to 3.
Lo 34
27. The protein as claimed in claim 13, comprising an amino acid sequence @:ccording to Seq. ID No. 2.
28. A method for identifying a compound which stimulates the activity of a GLUT4 S protein, which comprises the steps: a) providing a yeast cell as claimed in one or more of claims 14 to 17, b) providing a chemical compound, c) contacting the yeast of a) with the chemical compound of b), d) determining glucose uptake by the yeast of c), e) relating the detected value of the glucose uptake of d) to the detected value of glucose uptake in a yeast cell as claimed in a) which is not contacted with a chemical compound as claimed in b), with a compound which causes an increase in the amount of glucose taken up in the yeast as claimed in d) stimulating the activity of said GLUT4 protein.
29. A pharmaceutical comprising a compound, which is identified by means of a method as claimed in claim 28, and additives and excipients for formulating a pharmaceutical.
30. The use of a compound which has been identified by means of a method as claimed in claim 28 for preparing a pharmaceutical for the treatment of type | and/or Il diabetes.
31. A method for identifying a compound inhibiting the corresponding protein of the Fgy1 gene, which comprises the steps: a) providing a yeast cell as claimed in one or more of claims 7 to 10 which contains a GLUT 4 protein, b) providing a chemical compound c) contacting the yeast of a) with the chemical compound of b), d) determining glucose uptake by the yeast of c), e) relating the detected value of the glucose uptake of d) to the detected value of glucose uptake in a yeast cell as claimed in a) which is not contacted with a chemical compound as claimed in b), with a compound which causes an
Co 35 increase in the amount of glucose taken up in the yeast as claimed in d) Qo stimulating the activity of a protein Fgy1.
32. A pharmaceutical comprising a compound which has been identified by means of amethod as claimed in claim 31, and additives and excipients for formulating a pharmaceutical.
33. The use of a compound which has been identified by means of a method as claimed in claim 31 for preparing a pharmaceutical for the treatment of diabetes.
34. A method for identifying a compound which inhibits the protein encoded by the ERG4 gene, which method comprises the steps: a) providing a yeast cell as claimed in one or more of claims 22 to 25, b) providing a chemical compound c) contacting the yeast of a) with the chemical compound of b), d) determining glucose uptake by the yeast of c), e) relating the detected value of the glucose uptake of d) to the detected value of glucose uptake in a yeast cell as claimed in a) which is not contacted with a chemical compound as claimed in b), with a compound which causes an increase in the amount of glucose taken up in the yeast as claimed in d) inhibiting the activity of a protein Erg4.
35. A pharmaceutical comprising a compound which has been identified by means of a method as claimed in claim 34, and additives and excipients for formulating a pharmaceutical.
36. The use of a compound which has been identified by means of a method as claimed in claim 34 for preparing a pharmaceutical for the treatment of diabetes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10242763A DE10242763A1 (en) | 2002-09-14 | 2002-09-14 | New polynucleotide encoding mutant human glucose transporter, useful for identifying antidiabetic agents that can be used to treat diabetes types I or II |
PCT/EP2003/009812 WO2004026907A2 (en) | 2002-09-14 | 2003-09-04 | Use of saccharomyces cerevisiae erg4 mutants for the expression of glucose transporters from mammals |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200501871B true ZA200501871B (en) | 2005-10-26 |
Family
ID=31724774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2005/01871A ZA200501871B (en) | 2002-09-14 | 2005-03-04 | Use of saccharomyces cerevisiae erg4 mutants for the expression of glucose transporters from mammals |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1539958A2 (en) |
JP (1) | JP4520854B2 (en) |
KR (1) | KR101233998B1 (en) |
CN (1) | CN1694960B (en) |
AU (1) | AU2003264257B2 (en) |
BR (1) | BR0314115A (en) |
CA (1) | CA2498636C (en) |
DE (1) | DE10242763A1 (en) |
HK (1) | HK1084401A1 (en) |
IL (2) | IL167321A (en) |
MX (1) | MXPA05002816A (en) |
NO (1) | NO20051795L (en) |
RU (1) | RU2345136C2 (en) |
WO (1) | WO2004026907A2 (en) |
ZA (1) | ZA200501871B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102899328A (en) * | 2012-09-28 | 2013-01-30 | 南京农业大学 | Goat glucose transporter 4 gene as well as recombinant expression vector and application of gene |
CN110408616B (en) * | 2019-07-09 | 2021-06-15 | 中南民族大学 | GLUT4 gene knockout sgRNA and A549 cell lines and construction method thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5942398A (en) * | 1998-02-26 | 1999-08-24 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding glutx and uses thereof |
EP1189943A1 (en) * | 1999-06-09 | 2002-03-27 | Whitehead Institute For Biomedical Research | Method of measuring plasma membrane targeting of glut4 |
DE10106718A1 (en) * | 2001-02-14 | 2002-09-05 | Aventis Pharma Gmbh | Yeast strain of Saccharomyces cerevisiae with functional expression of a glow transporter |
-
2002
- 2002-09-14 DE DE10242763A patent/DE10242763A1/en not_active Withdrawn
-
2003
- 2003-09-04 CN CN038251485A patent/CN1694960B/en not_active Expired - Fee Related
- 2003-09-04 EP EP03797264A patent/EP1539958A2/en not_active Withdrawn
- 2003-09-04 CA CA2498636A patent/CA2498636C/en not_active Expired - Fee Related
- 2003-09-04 BR BR0314115-2A patent/BR0314115A/en not_active IP Right Cessation
- 2003-09-04 KR KR1020057004292A patent/KR101233998B1/en not_active IP Right Cessation
- 2003-09-04 WO PCT/EP2003/009812 patent/WO2004026907A2/en active Application Filing
- 2003-09-04 AU AU2003264257A patent/AU2003264257B2/en not_active Ceased
- 2003-09-04 JP JP2004536979A patent/JP4520854B2/en not_active Expired - Fee Related
- 2003-09-04 RU RU2005110955/13A patent/RU2345136C2/en not_active IP Right Cessation
- 2003-09-04 MX MXPA05002816A patent/MXPA05002816A/en active IP Right Grant
-
2005
- 2005-03-04 ZA ZA2005/01871A patent/ZA200501871B/en unknown
- 2005-03-08 IL IL167321A patent/IL167321A/en not_active IP Right Cessation
- 2005-04-12 NO NO20051795A patent/NO20051795L/en not_active Application Discontinuation
-
2006
- 2006-04-18 HK HK06104586.6A patent/HK1084401A1/en not_active IP Right Cessation
-
2009
- 2009-03-16 IL IL197621A patent/IL197621A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL197621A (en) | 2014-01-30 |
KR20050056206A (en) | 2005-06-14 |
BR0314115A (en) | 2005-07-12 |
RU2345136C2 (en) | 2009-01-27 |
IL197621A0 (en) | 2011-08-01 |
KR101233998B1 (en) | 2013-02-18 |
RU2005110955A (en) | 2006-01-20 |
NO20051795L (en) | 2005-06-08 |
HK1084401A1 (en) | 2006-07-28 |
WO2004026907A2 (en) | 2004-04-01 |
JP2006517088A (en) | 2006-07-20 |
AU2003264257B2 (en) | 2010-05-20 |
MXPA05002816A (en) | 2005-05-27 |
CA2498636A1 (en) | 2004-04-01 |
DE10242763A1 (en) | 2004-03-18 |
CN1694960A (en) | 2005-11-09 |
JP4520854B2 (en) | 2010-08-11 |
CA2498636C (en) | 2012-04-17 |
WO2004026907A3 (en) | 2004-11-11 |
IL167321A (en) | 2013-11-28 |
CN1694960B (en) | 2010-05-12 |
AU2003264257A1 (en) | 2004-04-08 |
EP1539958A2 (en) | 2005-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xu et al. | DNA sequencing of the seven remaining structural genes of the gene cluster encoding the energy-transducing NADH-quinone oxidoreductase of Paracoccus denitrificans | |
US11702627B2 (en) | High cAMP yielding yeast strain and use thereof | |
Hamada et al. | Isolation and characterization of a novel secretory protein, stromal cell-derived factor-2 (SDF-2) using the signal sequence trap method | |
CN102816244A (en) | Fusion protein of exendin-4 peptide and human serum albumin (HSA) and preparation method thereof | |
KR20210128742A (en) | Recombinant Acid Resistant Yeast Inhibited Glycerol Production and Method for Preparing Lactic Acid Using The Same | |
KR20210041903A (en) | Recombinant Acid Resistant Yeast Inhibited Lactate Metabolism and Alcohol Production and Method for Preparing Lactic Acid Using The Same | |
US8298812B2 (en) | Use of Saccharomyces cerevisiae erg4 mutants for expressing mammalian glucose transporters | |
JP4287897B2 (en) | Yeast strain Saccharomyces cerevisiae in which the GLUT transporter is functionally expressed | |
CN101525387B (en) | Recombined long-acting glucagons peptide analogue and preparation method thereof | |
CN113735960B (en) | Application of FGF recombinant protein in treating NASH | |
CN1178950C (en) | Corpuscles of stannius protein, stanniocalcin | |
ZA200501871B (en) | Use of saccharomyces cerevisiae erg4 mutants for the expression of glucose transporters from mammals | |
CN111411095B (en) | Recombinant (R) -omega-transaminase, mutant and application thereof | |
KR101903553B1 (en) | Method for production of medium chain aminocarboxylic acid | |
CN109628476A (en) | A method of 4-hydroxyisoleucine is produced using resting cell | |
CN115838645A (en) | Yeast strain for high yield of orotic acid and application thereof | |
CN1332240A (en) | Superoxide dismutase-4 | |
EP0590721B1 (en) | Method for expressing receptors of the human nervous system in the yeast Schizosaccharomyces pombe | |
TWI323281B (en) | Saccharomyces cerevisiae yeast strain with functional expression of a glut transporter | |
KR20070027878A (en) | Method for manufacturing xylitol with high-yield | |
WO2001031023A1 (en) | A novel polypeptide-human nucleoprotein ii precursor protein 25 and the polynucleotide encoding said polypeptide |